Identification of Epigenetic Biomarkers for Early Detection of Rheumatic Disease

Status unconfirmed

Conditions studied: Arthritis, Rheumatoid

In brief

• Given the cost and risk associated with biologic disease modifying anti-rheumatic drugs (bDMARDs), selection of the optimal medication is imperative. Current attempts to identify genetic factors that predict bDMARD response and effectiveness in rheumatoid arthritis patients have been inconclusive. Furthermore the presence of epigenetic signatures in rheumatoid arthritis patients has not been established. This protocol is the first step to identifying the practicality and feasibility of epigenetic testing to aid in diagnosis and/or medication selection in rheumatoid arthritis patients. Subsequent research into such epigenetic changes may be indicative of bDMARD response and/or safety. If such epigenetic signatures (EGS) exist the business need for such tests will thus be supported.

Key facts

Study ID

NCT02742337

Run by

Arthritis Northwest PLLC

People needed

30

Starts

2015-10-01

Expected to finish

2016-09-01

Last updated by the study team

2016-04-19

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: accepted.

You may not qualify if…

• Male
• Age 17 or less
• History of Disease Modifying Anti-Rheumatic Drugs (DMARDs), or biologic DMARDs.
• History of malignancy, except non-melanoma skin cancer
• Previous treatment for malignancy with chemotherapy agents
• Patient reported history of HIV, HepB, HepC, or TB

Where it is running

• Arthritis Northwest — Spokane, Washington, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.